Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Amine-constrained pyridazinone histamine H₃ receptor antagonists.
Sundar BG, Bailey T, Bacon E, Aimone L, Huang Z, Lyons J, Raddatz R, Hudkins R. Sundar BG, et al. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5543-6. doi: 10.1016/j.bmcl.2011.06.094. Epub 2011 Jul 22. Bioorg Med Chem Lett. 2011. PMID: 21824776
Targeting the JNK pathway for therapeutic benefit in CNS disease.
Bozyczko-Coyne D, Saporito MS, Hudkins RL. Bozyczko-Coyne D, et al. Among authors: hudkins rl. Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):31-49. doi: 10.2174/1568007023339472. Curr Drug Targets CNS Neurol Disord. 2002. PMID: 12769633 Review.
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M. Hudkins RL, et al. J Med Chem. 2011 Jul 14;54(13):4781-92. doi: 10.1021/jm200401v. Epub 2011 Jun 2. J Med Chem. 2011. PMID: 21634396
61 results